• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接种时间间隔对广州SARS-CoV-2奥密克戎变异株感染的影响:一项真实世界匹配病例对照研究

Effect of Vaccination Time Intervals on SARS-COV-2 Omicron Variant Strain Infection in Guangzhou: A Real-World Matched Case-Control Study.

作者信息

Li Yufen, Guo Tong, Zhong Jiayi, Fang Chuanjun, Xiong Husheng, Hu Zengyun, Zhu Yajuan, Tan Jinlin, Liu Shuang, Jing Qinlong, Zhang Dingmei

机构信息

Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.

Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China.

出版信息

Vaccines (Basel). 2022 Nov 1;10(11):1855. doi: 10.3390/vaccines10111855.

DOI:10.3390/vaccines10111855
PMID:36366363
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9693306/
Abstract

In April 2022, a COVID-19 outbreak caused by the Omicron variant emerged in Guangzhou. A case-control study was conducted to explore the relationship between vaccination intervals and SARS-CoV-2 infection in the real world. According to the vaccination dose and age information of the cases, a 1:4 matched case-control sample was established, finally including n = 242 for the case group and n = 968 for the control group. The results indicated that among the participants who received three vaccine doses, those with an interval of more than 300 days between the receipt of the first vaccine dose and infection (or the first contact with a confirmed case) were less likely to be infected with SARS-CoV-2 than those with an interval of less than 300 days ( = 0.67, 95% = 0.46-0.99). After age-stratified analysis, among participants aged 18-40 years who received two doses of vaccine, those who received the second dose more than 30 days after the first dose were less likely to be infected with SARS-CoV-2 ( = 0.53, 95% = 0.30-0.96). Our findings suggest that we need to extend the interval between the first dose and the second dose and further explore the optimal interval between the first and second and between the second and third doses in order to improve vaccine efficacy.

摘要

2022年4月,广州出现了由奥密克戎变种引发的新冠疫情。开展了一项病例对照研究,以探讨现实世界中疫苗接种间隔与新型冠状病毒感染之间的关系。根据病例的疫苗接种剂量和年龄信息,建立了1:4匹配的病例对照样本,最终病例组包括n = 242例,对照组包括n = 968例。结果表明,在接种三剂疫苗的参与者中,首次接种疫苗至感染(或首次接触确诊病例)间隔超过300天的人感染新型冠状病毒的可能性低于间隔少于300天的人(比值比 = 0.67,95%置信区间 = 0.46 - 0.99)。经过年龄分层分析,在接种两剂疫苗的18 - 40岁参与者中,第一剂接种后30天以上接种第二剂的人感染新型冠状病毒的可能性较小(比值比 = 0.53,95%置信区间 = 0.30 - 0.96)。我们的研究结果表明,需要延长第一剂和第二剂之间的间隔,并进一步探索第一剂与第二剂以及第二剂与第三剂之间的最佳间隔,以提高疫苗效力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73ba/9693306/228ec01272c1/vaccines-10-01855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73ba/9693306/228ec01272c1/vaccines-10-01855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73ba/9693306/228ec01272c1/vaccines-10-01855-g001.jpg

相似文献

1
Effect of Vaccination Time Intervals on SARS-COV-2 Omicron Variant Strain Infection in Guangzhou: A Real-World Matched Case-Control Study.接种时间间隔对广州SARS-CoV-2奥密克戎变异株感染的影响:一项真实世界匹配病例对照研究
Vaccines (Basel). 2022 Nov 1;10(11):1855. doi: 10.3390/vaccines10111855.
2
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
3
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间,mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络,10 个州,2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
4
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.在中国,两剂科兴新冠疫苗后接种一剂mRNA和三种平台型新冠疫苗作为第三剂的免疫原性、持久性和安全性:一项随机、双盲、安慰剂对照的2期试验。
EClinicalMedicine. 2022 Sep 28;54:101680. doi: 10.1016/j.eclinm.2022.101680. eCollection 2022 Dec.
5
[Characteristics and related factors of viral nucleic acid negative conversion in children infected with Omicron variant strain of SARS-CoV-2].[新型冠状病毒奥密克戎变异株感染儿童病毒核酸转阴的特征及相关因素]
Zhonghua Er Ke Za Zhi. 2022 Dec 2;60(12):1307-1311. doi: 10.3760/cma.j.cn112140-20220623-00582.
6
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间,接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
7
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.在奥密克戎毒株占主导期间,既往BNT162b2型新冠疫苗接种与儿童及青少年有症状的新冠病毒感染之间的关联
JAMA. 2022 Jun 14;327(22):2210-2219. doi: 10.1001/jama.2022.7493.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.在广州,灭活的 SARS-CoV-2 疫苗对 Delta 变异株感染的有效性:一项病例对照的真实世界研究。
Emerg Microbes Infect. 2021 Dec;10(1):1751-1759. doi: 10.1080/22221751.2021.1969291.
10
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.COVID-19 加强针接种后免疫反应的持久性及其与 COVID-19 奥密克戎感染的关联。
JAMA Netw Open. 2022 Sep 1;5(9):e2231778. doi: 10.1001/jamanetworkopen.2022.31778.

本文引用的文献

1
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis.新冠疫苗对现实世界中关注的 SARS-CoV-2 变异株的有效性:文献综述和荟萃分析。
Emerg Microbes Infect. 2022 Dec;11(1):2383-2392. doi: 10.1080/22221751.2022.2122582.
2
Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.在接种两剂科兴疫苗后,泰国医护人员接种一剂 BNT162b2 异源加强针后抗刺突受体结合域(RBD)水平和短期不良事件的动态变化。
Vaccine. 2022 May 9;40(21):2915-2924. doi: 10.1016/j.vaccine.2022.04.020. Epub 2022 Apr 13.
3
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.
SARS-CoV-2 BA.1 变异株被疫苗加强针诱导的血清中和,但逃避了大多数恢复期血清和治疗性抗体。
Sci Transl Med. 2022 May 18;14(645):eabn8543. doi: 10.1126/scitranslmed.abn8543.
4
Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2.评估两剂疫苗接种方案中剂量之间的最佳时间间隔,以减少正在流行的SARS-CoV-2疫情中的死亡人数。
PLoS Comput Biol. 2022 Mar 25;18(3):e1009978. doi: 10.1371/journal.pcbi.1009978. eCollection 2022 Mar.
5
Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.SARS-CoV-2 mRNA 疫苗接种后 6 个月体液免疫应答显著下降的特征:系统评价。
J Med Virol. 2022 Jul;94(7):2939-2961. doi: 10.1002/jmv.27688. Epub 2022 Mar 9.
6
SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore.新加坡接种三剂BNT162b2 mRNA新冠疫苗90天后的SARS-CoV-2刺突蛋白和中和抗体动力学
Vaccines (Basel). 2022 Feb 18;10(2):331. doi: 10.3390/vaccines10020331.
7
Extended interval BNT162b2 vaccination enhances peak antibody generation.延长间隔接种BNT162b2疫苗可增强抗体峰值生成。
NPJ Vaccines. 2022 Jan 27;7(1):14. doi: 10.1038/s41541-022-00432-w.
8
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.奥密克戎变异株(B.1.1.529):传染性、疫苗突破和抗体耐药性。
J Chem Inf Model. 2022 Jan 24;62(2):412-422. doi: 10.1021/acs.jcim.1c01451. Epub 2022 Jan 6.
9
Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.BNT162b2 mRNA COVID-19 疫苗的抗体反应动力学:7 个月随访研究。
Medicina (Kaunas). 2021 Dec 5;57(12):1330. doi: 10.3390/medicina57121330.
10
OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear.奥密克戎(B.1.1.529):一种引起全球恐慌的新型关注变异株。
J Med Virol. 2022 May;94(5):1821-1824. doi: 10.1002/jmv.27541. Epub 2021 Dec 30.